Michael R. Green

The paper establishes a PDX repository of large B-cell lymphoma models capturing clinical and molecular diversity, including post-CART19 progression cases.

The paper identifies a proteomic signature of mantle cell lymphoma (MCL) using quantitative proteomics, revealing 10 upregulated proteins that may serve as therapeutic targets.

The paper develops bivalent molecules that convert kinase inhibitors into activators of proapoptotic genes, achieving selective killing of DLBCL cells with low cytotoxicity.

The paper shows that CREBBP mutations disrupt chromatin loading dynamics and EP300 redundancy, creating zombie enzymes that impair enhancer activation in GC B-cells and lymphoma.

The paper identifies dysfunctional CD8 CAR T-cells in rrLBCL tumors and shows that pegenzileukin mitigates this dysfunction, improving CAR T-cell responses.

The paper identifies TCF4 overexpression driven by 18q21.2 gains as a mechanism promoting IgM expression in ABC-like DLBCL and shows BET inhibitors can suppress it.